<DOC>
	<DOC>NCT00329537</DOC>
	<brief_summary>The purpose of this study is to assess the tolerability, pharmacokinetics and safety of 2 and 6 micro g/kg/day sargramostim administered subcutaneously once daily for 4 weeks, and to assess the efficacy and safety of 6 micro g/kg/day sargramostim administered subcutaneously once daily for 8 weeks in comparison with placebo, in patients with moderately to severely active Crohn's disease.</brief_summary>
	<brief_title>Study of Sargramostim in Moderately to Severely Active Crohn's Disease</brief_title>
	<detailed_description>On 29 May 2009, Bayer began transitioning the sponsorship of this trial to Genzyme. NOTE: This study was originally posted by sponsor Berlex, Inc. Berlex, Inc. was renamed to Bayer HealthCare, Inc.</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Confirmed diagnosis of Crohn's disease (endoscopic or radiological evaluation) at least 4 months prior to receiving the first dose of study drug Moderately to severely active Crohn's disease at time of screening (i.e., Crohn's disease activity index [CDAI] &gt;220 and &lt;475 points) Colostomy or ileostomy Immediate need for gastrointestinal (GI) surgery for active GI bleeding, peritonitis, intestinal obstruction, or intraabdominal or perianal abscess requiring surgical drainage GI surgery within 6 months prior to receiving the 1st dose of study drug Symptoms of bowel obstruction or confirmed evidence of a clinicallysignificant stricture within the last 6 months that has not been surgically corrected</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Crohn's Disease</keyword>
	<keyword>Sargramostim</keyword>
	<keyword>CDAI</keyword>
	<keyword>Moderately to severely active Crohn's Disease</keyword>
</DOC>